2015年度以第一通讯作者身份共发表SCI论著99篇

发布者: 发布时间:2016-4-2 19:38:56 阅读:405次

2015年度以第一通讯作者身份共发表SCI论著99篇,详见以下清单:

1. Chen YP,# Wang ZX,# Chen L,# Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J.* A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol, 2015; 26(1): 205-211. (IF 7.0)
2. Lan M, Huang Y, Chen CY, Han F, Wu SX, Tian L, Zheng L, Lu TX.* Prognostic value of cervical nodal necrosis in nasopharyngeal carcinoma: analysis of 1800 patients with positive cervical nodal metastasis at MR imaging. Radiology, 2015; 276(2): 536-619. (IF 6.9)
3. Zeng L, Huang SM, Tian YM, Sun XM, Han F, Lu TX, Deng XW.* Normal tissue complication probability model for radiation induced temporal lobe injury after intensity-modulated radiation therapy for nasopharyngeal carcinoma. Radiology, 2015; 267(1): 243-249. (IF 6.9)
4. Wu SG, Rao MY, Zhou J, Lin Q, Wang ZJ, Chen YX, He ZY.* Distribution of metastatic disease in the brain in relation to the hippocampus: a retrospective single-center analysis of 6064 metastases in 632 patients. Oncotarget, 2015; 6(41): 44030-44036. (IF 6.4)
5. Zhang LN, Gao YH, Lan XW, Tang J, Su Z, Ma J, Deng W, OuYang PY,* Xie FY.* Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Oncotarget, 2015; 6(41): 44019-44029. (IF 6.4)
6. Zeng L, Guo P, Li JG, Han F, Li Q, Lu Y, Deng XW, Zhang QY,* Lu TX.* Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy. Oncotarget, 2015; 6(36): 39373-39383. (IF 6.4)
7. Wu SG,# Sun JY,# Yang LC, Zhou J, Li FY, Li Q, Lin HX, Lin Q, He ZY.* Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes. Oncotarget, 2015; 6(34): 36911-36922. (IF 6.4)
8. Guan Y,# Li A,# Xiao W,3 Liu S, Chen B, Lu T, Zhao C,* Han F.* The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget, 2015; 6(32): 33926-33934. (IF 6.4)
9. He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ, Xie D.* Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget, 2015; 6(31): 31181-31190. (IF 6.4)
10. Wang L, Wang H, Wang JH, Xia ZJ, Lu Y, Huang HQ, Jiang WQ, Zhang YJ. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodalNK/T cell lymphoma in the era of asparaginase. Oncotarget, 2015; 6(30): 30317-30326. (IF 6.4)
11. Chen YP,# Zhang WN,# Chen L,# Tang LL, Mao YP, Li WF, Liu X, Zhou GQ, Sun Y, Kang TB, Zeng MS, Liu N,* Ma J.* Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget, 2015; 6(30): 29311-29323. (IF 6.4)
12. Li AC,# Xiao WW,# Shen GZ,# Wang L, Xu AA, Cao YQ, Huang SM, Lin CG, Han F,* Deng XW,* Zhao C.* Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget, 2015; 6(27): 24511-24521. (IF 6.4)
13. Li YQ,# Li WF,# He QM, Xu YF, Ren XY, Tang XR, Wen X, Yang XJ, Sun Y, Zeng J, Yun JP, Liu N,* Ma J.* MET overexpression and proliferation predict poor prognosis in patients with locoregional advanced nasopharyngeal carcinoma. Oncotarget, 2015; 6(15): 13309-13319. (IF 6.4)
14. Tan GS,# Cao XP,# Dai QS, Zhang B, Huang JW, Xiong SQ, Zhang YY, Chen W, Yang JY, Li HP.* A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget, 2015; 6(11): 8676-8686. (IF 6.4)
15. He ZY, Wu SG, Yang Q, Sun JY, Li FY, Lin Q, Lin HX.* Breast cancer subtype is associated with axillary lymph node metastasis: a retrospective cohort study. Medicine, 2015; 94(48): e2213. (IF 5.7)
16. Chen YP,# Tang LL,# Zhang WN,# Mao YP, Chen L, Sun Y, Liu LZ, Li WF, Liu X, Zhou GQ, Guo R, Mai HQ, Shao JY, Lin AH, Li L, Ma J.* Prognostic value and grading of MRI-based T category in patients with nasopharyngeal carcinoma without lymph node metastasis undergoing intensity-modulated radiation therapy. Medicine, 2015; 94(43):e1624. (IF 5.7)
17. Zhang WN,# Chen YP,# Zhou GQ,# Liu X, Chen L, Tang LL, Mao YP, Sun Y, Ma J.* Pretreatment serum lactate dehydrogenase and N classification predict long-term survival and distant metastasis in patients with nasopharyngeal carcinoma who have a positive family history of cancer. Medicine, 2015; 94(37): e1505. (IF 5.7)
18. Zhang LL,# Mao YP,# Zhou GQ, Tang LL, Qi ZY, Lin L, Yao JJ, Ma J, Lin AH, Sun Y.* The Evolution of and Risk Factors for Neck Muscle Atrophy and Weakness in Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy: A Retrospective Study in An Endemic Area. Medicine, 2015; 94(31): e1294. (IF 5.7)
19. Zhang WN,# Chen YP,# Chen L,# Guo R, Zhou GQ, Tang LL, Mao YP, Li WF, Liu X, Du XJ, Sun Y, Ma J.* The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: The dawn of a new era? A systematic review and meta-analysis of 7,836 cases.  Medicine, 2015; 94(20): e845. (IF 5.7)
20. Jiang W,# Liu N,# Chen XZ,# Sun Y,# Li B, Ren XY, Qin WF, Jiang N, Xu YF, Li YQ, Ren J, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Mai HQ, Zeng MS, Kang TB, Jia WH, Shao JY, Ma J.* Genome-wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. Mol Cancer Ther, 2015; 14(12): 2864-2873. (IF 5.7)
21. Xu YF,# Mao YP,# Li YQ, Ren XY, He QM, Tang XR, Sun Y, Liu N,* Ma J.* MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting Disabled homolog-2. Cancer Lett, 2015; 363(2): 146-155. (IF 5.6)
22. Zhang LL,# Wang XJ,# Zhou GQ, Tang LL, Lin AH, Ma J, Sun Y.* Dose-volume relationships for moderate or severe neck muscle atrophy after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma. Sci Rep, 2015; 5: 18415. (IF 5.6)
23. Zhang F,# Zhang Y,# Li WF, Liu X, Guo R, Sun Y, Lin AH, Chen L, Ma J.* Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis. Sci Rep, 2015; 5: 17378. (IF 5.6)
24. Du XJ,# Tang LL,# Chen L, Mao YP, Guo R, Liu X, Sun Y, Zeng MS, Kang TB, Shao JY, Lin AH, Ma J.* Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Sci Rep, 2015; 5: 16664. (IF 5.6)
25. Yang L,# Hong S,# Wang Y,# Chen H, Liang S, Peng P, Chen Y.* Development and external validation of nomograms for predicting survival in nasopharyngeal carcinoma patients after definitive radiotherapy. Sci Rep, 2015; 5: 15638. (IF 5.6)
26. Zhang Y,# Li WF,# Chen L, Mao YP, Guo R, Zhang F, Peng H, Liu LZ, Li L, Liu Q, Ma J.* Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Sci Rep, 2015; 5: 13919. (IF 5.6)
27. Yao JJ,# Zhou GQ,# Lin L, Zhang WJ, Peng YL, Chen L, Tang LL, Mao YP, Ma J, Sun Y.* Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. Sci Rep, 2015; 5: 13525. (IF 5.6) 
28. Chen YP,# Chen Y,# Zhang WN,# Liang SB, Zong JF, Chen L, Mao YP, Tang  LL, Li WF, Liu X, Guo Y, Lin AH, Liu MZ, Sun Y, Ma J *. Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial. Sci Rep, 2015; 5: 12502. (IF 5.6)
29. Zhang Y,# Liu X,# Zhang Y,# Li WF, Chen L, Mao YP, Shen JX, Zhang F, Peng H, Liu Q, Sun Y, Ma J.* Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. Sci Rep, 2015; 5: 12242. ( IF 5.6)
30. Zhang WW,# Zhu YJ,# Yang H, Wang QX, Wang XH, Xiao WW, Li QQ, Liu MZ, Hu YH.* Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma. Sci Rep, 2015; 5: 8071. (IF 5.6)
31. Li YQ,# Ren XY,# He QM, Xu YF, Tang XR, Sun Y, Zeng MS, Kang TB, Liu N,* Ma J.* MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. Cell Death Dis, 2015; 6: e1618. (IF 5.0)
32. OuYang PY,# Zhang LN,# Lan XW,# Xie C, Zhang WW, Wang QX, Su Z, Tang J, Xie FY.* The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer, 2015; 112: 1554-1561. (IF 4.8)
33. Ren XY,# Zhou GQ,# Jiang W,# Sun Y, Xu YF, Li YQ, Tang XR, Wen X, He QM, Yang XJ, Liu N,* Ma J.* Low SFRP1 expression correlates with poor prognosis and promotes cell invasion by activating the Wnt-β-catenin signaling pathway in NPC. Cancer Prev Res, 2015; 8(10): 968-977. (IF 4.4)
34. Liu SL,# Yang H,# Zhang P,# Zhang L, Zhao L, Luo LL, Fu JH, Liu MZ, Xi M.* Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: a matched case–control study. Radiother Oncol, 2015; 116(2): 262-268. (IF 4.4)
35. Zhang P,# Xi M,# Zhao L, Qiu B, Liu H, Hu YH, Liu MZ.* Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol, 2015; 116(2): 257-261. (IF 4.4)
36. Tang LL,# Chen L,# Mao YP, Li WF, Sun Y, Liu LZ, Lin AH, Mai HQ, Shao JY, Li L, Ma J.* Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiother Oncol, 2015; 116(2): 167-173. (IF 4.4)
37. Chen YP,# Sun Y,# Chen L,# Mao YP, Tang LL, Li WF, Liu X, Zhang WN, Guo R, Lin AH, Ma J.* Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: meta-analysis of randomised controlled trial. Radiother Oncol, 2015; 116(2): 157-166. (IF 4.4)
38. Cheng YK,# Zhang F,# Tang LL, Chen L, Zhou GQ, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Guo Y, Ma J.* Pregnancy associated nasopharyngeal carcinoma: a retrospective case-control analysis of maternal survival outcomes. Radiother Oncol, 2015; 116(1): 125-130. (IF 4.4)
39. Tao CJ, Yi JL, Chen NY, Ren W, Cheng J, Tung S, Kong L, Lin SJ, Pan JJ, Zhang GS, Hu J, Qi ZY, Ma J, Lu JD, Yan D, Sun Y.* Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: a multi-institution clinical study. Radiother Oncol, 2015; 115(3): 407-411. (IF 4.4)
40. Guo R,# Chen XZ,# Chen L, Jiang F, Tang LL, Mao YP, Zhou GQ, Li WF, Liu LZ, Tian L, Lin AH, Ma J.* Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: development and validation of a predictive score model. Radiother Oncol, 2015; 114(2): 249-256. (IF 4.4)
41. Bao Y,# Peng F,# Zhou QC,# Yu ZH, Li JC, Cheng ZB, Chen L, Hu X, Chen YY, Wang J, Wang Y, Ma HL, Xu ZM, Lu RB, Deng XW, Chen M.* Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol, 2015; 114(2): 161-166. (IF 4.4)
42. Wu SG,# Wang Y,# Zhou J, Sun JY, Li FY, Lin HX, He ZY.* Number of negative lymph nodes should be considered for incorporation into staging for breast cancer. Am J Cancer Res, 2015; 5(2): 844-853. (IF 4.2)
43. Xu YF,# Li YQ,# Guo R,# He QM, Ren XY, Tang XR, Jia WH, Kang TB, Zeng MS, Sun Y, Ma J,* Liu N.* Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. Int J Biochem Cell Biol, 2015; 61: 120-128. (IF 4.0)
44. Du XJ,# Tang LL,# Mao YP, Guo R, Sun Y, Lin AH, Ma J.* Value of prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med, 2015; 13(1): 364. (IF 3.9)
45. Wu SG,# Li FY,# Zhou J, Lin Q, Sun JY, Lin HX, Guan XX, He ZY.* Prognostic value of different lymph node staging methods in esophageal squamous cell carcinoma after esophagectomy. Ann Thorac Surg, 2015; 99(1): 284-290. (IF 3.8)
46. Zhang H, Zhao L,* Wang YX, Xi M, Liu SL, Luo LL. Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma. Tumour Biol, 2015; 36(11): 8805-8809. (IF 3.6)
47. Li AC,# Xiao WW,# Wang L, Shen GZ, Xu AA, Cao YQ, Huang SM, Lin CG, Han F,* Deng XW,* Zhao C.* Risk factors and prediction-score model for distant metastasis in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Tumour Biol, 2015; 36(11): 8349-8357. (IF 3.6)
48. Zhang LN,# Xiao W,# OuYang PY,# You K, Zeng ZF, Ding PR, Pan ZZ, Xu RH, Gao YH.* The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy. Tumour Biol, 2015; 36(10): 8213-8219. (IF 3.6)
49. Yang L,# Li F,# Lei F, Wang Y, Wu S, Song L, Chen Y.* Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumour Biol, 2015; 36(10): 7977-7986. (IF 3.6)
50. Wang L,# Wang Z,# Xia ZJ, Lu Y, Huang HQ, Zhang YJ.* CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Tumour Biol, 2015; 36(10): 7717-7723. (IF 3.6)
51. Zhang LN, Gao YH, Lan XW, Tang J, OuYang PY,* Xie FY.* Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol, 2015; 51(10): 950-956. (IF 3.6)
52. Xiao WW,# Xu AA,# Han F, Lin XP, Lu LX, Shen GZ, Huang SM, Fan W, Deng XW,* Zhao C.* Positron emission tomography–computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: A prospective study with long-term follow-up. Oral Oncol, 2015; 51(4): 363-369. (IF 3.6)
53. Chen YP,# Zhang WN,# Tang LL,# Mao YP, Liu X, Chen L, Zhou GQ, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Sun Y, Ma J.* Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. BMC Cancer, 2015; 15(1): 930. (IF 3.4)
54. Li WF,# Li YQ,# Chen L, Zhang Y, Guo R, Zhang F, Peng H, Sun Y, Ma J.* Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. BMC Cancer, 2015; 15: 810. (IF 3.4)
55. Zhang F,# Cheng YK,# Li WF, Guo R, Chen L, Sun Y, Mao YP, Zhou GQ, Liu X, Liu LZ, Lin AH, Tang LL,* Ma J.* Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. BMC Cancer, 2015; 15: 709. (IF 3.4)
56. Su Z,# Mao YP,# OuYang PY, Tang J, Lan XW, Xie FY.* Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer, 2015; 15: 429. (IF 3.4)
57. Xu YF,# Ren XY,# Li YQ, He QM, Tang XR, Sun Y, Shao JY, Jia WH, Kang TB, Zeng MS, Liu N,* Ma J.* High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer, 2015; 15: 332. (IF 3.4)
58. Chen Y,# Hu XF,# Wang Y, Chen HY, Yang L, Liu LZ, Cui CY, Liu DS, Liang SB.* Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal
carcinoma treated using intensity-modulated radiotherapy? BMC Cancer, 2015; 15: 305. (IF 3.4)
59. He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH.* Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer, 2015; 15: 111. (IF 3.4)
60. Wu SG,# Sun JY,# Zhou J, Li FY, Lin Q, Lin HX, Guan XX, He ZY.* Number of negative lymph nodes is associated with disease-free survival in patients with breast cancer. BMC Cancer, 2015; 15: 43. (IF 3.4)
61. Wu SG,# Li Q,# Zhou J, Sun JY, Li FY, Lin Q, Lin HX, Gaun XX, He ZY.* Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy. Cancer Res Treat, 2015; 47(4): 757-764. (IF 3.3)
62. Zhou J,# Wu SG,# Wang JJ, Sun JY, Li FY, Lin Q, Lin HX, He ZY.* Ovarian ablation using goserelin improves survival of premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea. Cancer Res Treat, 2015; 47(1): 55-63. (IF 3.3)
63. Zhou J, Yang LC, He ZY, Li FY, Wu SG, Sun JY.* Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer. J Cancer, 2015; 6(10): 970-975. (IF 3.3)
64. Chen YP,# Guo R,# Liu N,# Liu X, Mao YP, Tang LL, Zhou GQ, Lin AH, Sun Y, Ma J.* Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials. J Cancer, 2015; 6(9): 883-892. (IF 3.3)
65. Xiao WW,# Zhang LN,# You KY, Huang R, Yu X, Ding PR, Gao YH.* A low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in pathological T3N0 rectal cancer patients following total mesorectal excision. J Cancer, 2015; 6(7): 612-622. (IF 3.3)
66. Liang XX,# Li Q,# Su Z,# Lan XW, OuYang PY, Mao YP, Shi DB, Deng WG, Cheng ZB, Wang SY, Xie FY.* Significant prognostic impact of chemoradiotherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer, 2015; 6(6): 502-510. (IF 3.3)
67. Zhou J,# Ran J,# He ZY,# Quan S, Chen QH, Wu SG, Sun JY.* Tailoring pelvic lymphadenectomy for patients with Stage IA2, IB1, and IIA1 uterine cervical cancer. J Cancer, 2015; 6(4): 377-381. (IF 3.3)
68. Wu SG,# Peng F,# Zhou J,# Sun JY, Li FY, Lin Q, Lin HX, Bao Y,* He ZY.* Number of negative lymph nodes can predict survival after postmastectomy radiotherapy according to different breast cancer subtypes. J Cancer, 2015; 6(3): 261-269. (IF 3.3)
69. Li PJ,# Jin T,# Luo DH, Shen T, Mai DM, Hu WH,* Mo HY.* Effect of prolonged radiotherapy treatment time on survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. PLoS One, 2015; 10(10): e0141332. (IF 3.2)
70. Su Z,# Mao YP,# OuYang PY, Tang J, Xie FY.* Initial hyperleukocytosis and neutrophilia in nasopharyngeal carcinoma: incidence and prognostic impact. PLoS One, 2015; 10(9): e0136752. (IF 3.2)
71. Yao JJ,# Zhou GQ,# Yu XL, Tang LL, Chen L, Mao YP, Lin L, Zhang LL, Shao JY, Guo Y, Ma J, Sun Y.* Incidence of and risk factors for mastoiditis after intensity modulated radiotherapy in nasopharyngeal carcinoma. PLoS One, 2015; 10(6): e0131284. (IF 3.2)
72. Guo R, Tang LL, Mao YP, Zhou GQ, Qi ZY, Liu LZ, Lin AH, Liu MZ, Ma J,* Sun Y.* Clinical outcomes of volume-modulated arc therapy in 205 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities. PLoS One, 2015; 10(7): e0129679. (IF 3.2)
73. Xiao WW,# Liu S,# Tian YM,# Guan Y, Huang SM, Lin CG, Zhao C, Lu TX, Han F.* Prognostic significance of tumor volume in locally recurrent nasopharyngeal carcinoma treated with salvage intensity-modulated radiotherapy. PLoS One, 2015; 10(4): e0125351. (IF 3.2)
74. Li YQ, # He QM,# Ren XY, Tang XR, Xu YF, Wen X, Yang XJ, Ma J,* Liu N.* MiR-145 inhibits metastasis by targeting facin acting-bundling protein 1 in nasopharyngeal carcinoma. PLoS One, 2015; 10(3): e.0122228. (IF 3.2)
75. Wu S,# Lai Y,# He Z,# Zhou Y, Chen S, Dai M, Zhou J, Lin Q, Chi F.* Dosimetric Comparison of the Simultaneous Integrated Boost in Whole-Breast Irradiation after Breast-Conserving Surgery: IMRT, IMRT plus an Electron Boost and VMAT. PLoS One, 2015; 10(3): e0120811. (IF 3.2)
76. He ZY,# Wu SG,# Zhou J,# Li FY, Lin Q, Lin HX, Sun JY.* Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes. PLoS One, 2015; 10(3): e0119150. (IF 3.2)
77. You KY,# Huang R,# Zhang LN,# Ding PR, Xiao WW, Qiu B, Chang H, Zeng ZF, Pan ZZ, Gao YH.* Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response. J Cancer Res Clin Oncol, 2015; 141(4): 719-722. (IF 3.1)
78. Wang L, Xia ZJ, Lu Y, Wang QX, Niu SQ, Huang HQ, Zhang YJ.* A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma. Leuk Lymphoma, 2015; 56(11): 3038-3044. (IF 2.9)
79. Zhang K,# He X,# Zhou Y, Gao L, Qi Z, Chen J,* Gao X.* Atorvastatin ameliorates radiation-induced cardiac fibrosis in rats. Radiat Res, 2015; 184(6): 611-620. (IF 2.9)
80. Wang L, Xia ZJ, Lu Y, Zhang YJ.* Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type. Med Oncol, 2015; 32(1): 320. (IF 2.6)
81. Wen B,# Zhang L,# Wang C, Huang R, Peng H, Zhang T, Dong J, Xiao W, Zeng Z, Liu M, Gao Y.* Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Radiat Oncol, 2015; 10(1): 124. (IF 2.5)
82. Tu Z, Xu B, Qu C, Tao Y, Chen C, Hua W, Feng G, Chang H, Liu Z, Li G, Jiang C, Yi W, Zeng M, Xia Y.* BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. Radiat Oncol, 2015; 10(1): 123. (IF 2.5)
83. Liu S,# Qiu B,# Chen L, Wang F, Liang Y, Cai P, Zhang L, Chen Z, Liu S, Liu M, Liu H.* Radiotherapy for asymptomatic brain metastasis in NSCLC patients harboring EGFR mutation without prior TKI treatment. Radiat Oncol, 2015; 10(1):118. (IF 2.5)
84. Zhu JH,# Chen LX,# Chen AL, Luo GW, Deng XW, Liu XW.* Fast 3D dosimetric verifications based on an electronic portal imaging device using a GPU calculation engine. Radiat Oncol, 2015; 10: 85. (IF 2.5)
85. Li QW, Niu SQ, Wang HY, Wen G, Li YY, Xia YF, Zhang YJ.* Radiotherapy alone is associated with improved outcomes over surgery in the management of solitary plasmacytoma. Asian Pac J Cancer Prev, 2015; 16(9): 3741-3745. (IF 2.5)
86. Chen RW,# Xu YF,# Du XJ,# Liu N, Jiang N, Jiang W, Li YQ, He QM, Tang LL, Mao YP, Sun Y, Chen L,* Ma J.* CXCL12 genetic variants as a prognostic marker in nasopharyngeal carcinoma. Oncotargets Ther, 2015; 8: 2835-2842. (IF 2.3)
87. Qin J,# Wu SG,# Sun JY, Lin HX, He ZY, Li Q.* Effect of blood type on survival of Chinese patients with esophageal squamous cell carcinoma. Oncotargets Ther, 2015; 8: 947-953. (IF 2.3)
88. Chen YP,# Zhao BC,# Chen C,# Shen LJ, Gao J, Mai ZY, Chen MK, Chen G, Yan F, Liu S, Xia YF.* Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients. Chin J Cancer, 2015; 34(3): 137-146. (IF 2.2)
89. Luo LL,# Zhao L,# Xi M, He LR, Shen JX, Li QQ, Liu SL, Zhang P, Xie D, Liu MZ.* Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma. Chin J Cancer, 2015; 34(3): 47. (IF 2.2)
90. Tian YM,# Xiao WW,# Bai L, Liu XW, Zhao C, Lu TX, Han F.* Impact of primary tumor volume and location on the prognosis of patients with locally recurrent nasopharyngeal carcinoma. Chin J Cancer, 2015; 34(1): 21. (IF 2.2)
91. Mao YP,# Yin WJ,# Guo R, Zhang GS, Fang JL, Chi F, Qi ZY, Liu MZ, Ma J, Sun Y.* Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Chin J Cancer, 2015; 34(1): 16. (IF 2.2)
92. Zhao L,# Chi F,# Xi M, Shen JX, Li QQ, He LR, Liu SL, Liu MZ.* Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma. Biomed Pharmacother, 2015; 74: 148-152. (IF 2.0)
93. Zhao L,# Wang YX,# Xi M, Liu SL, Zhang P, Luo LL, Liu MZ.* Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population. Int J Clin Exp Pathol, 2015; 8(5): 5753-5760. (IF 1.9)
94. Zhang GY, Wang YJ, Liu JP, Zhou XH, Xu ZF, Chen XP, Xu T, Wei WH, Zhang Y, Huang Y.* Prognostic Value of Classifying Parapharyngeal Extension in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging. Biomed Res Int, 2015; 2015; 749515. (IF 1.6)
95. Li PJ, Hu WH, Zhu Y, Liu JJ.* Treatment and predictive factors in patients with recurrent laryngeal carcinoma: A retrospective study. Oncol Lett, 2015; 10(5): 3145-3152. (IF 1.6)
96. Chen YP, Chen C, Mai ZY, Gao J, Shen LJ, Zhao BC, Chen MK, Chen G, Yan F, Huang TY, Xia YF.* Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett, 2015; 9(3): 1458-1466. (IF 1.6)
97. Zhou J, Zheng H, Wu SG, He ZY, Li FY, Su GQ, Sun JY.* Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: A retrospective cohort study. Int J Surg, 2015; 23(Pt A): 147-151. (IF 1.5)
98. Chi F,# Wu S,# Zhou J, Li F, Sun J, Lin Q, Lin H, Guan X, He Z.* Dosimetric comparison of moderate deep inspiration breath-hold and free-breathing intensity-modulated radiotherapy for left-sided breast cancer. Cancer Radiother, 2015; 19(3): 180-186. (IF 1.4)
99. Wang H, Zhang Z, Sun R, Lin H, Gong L, Fang M, Hu WH.* HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma. J Voice, 2015; 29(3): 356-362. (IF 1.2)
返回